Artificial intelligence is transforming how life sciences teams plan, execute, and scale commercial strategy—but the true differentiator isn’t the algorithm. It’s the data foundation behind it. In our latest blog, we ex...
Filter blogs
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Enhancing diversity in clinical trials
To fully assess the efficacy and safety of a therapeutic indication, clinical trials must evaluate populations that are representative of the treatment population, as different people may experience the same disease differently.
-
Utilising connected sensors to power diverse and equitable clinical trials
Our publication in Nature npj Digital Medicine outlines current evidence and a solution framework for diversity in research using digital health technologies.
-
Enabling a new way to select fit-for-purpose COAs to simplify clinical protocols
While digital health technologies are one piece of the clinical protocol puzzle, holistic protocol design requires more breadth.
-
The rise of precision outcome measures
Precision outcome measures are the means by which to evaluate a meaningful change on the exact outcome of interest, regardless of tool or instrument.
-
Tested, tried and true: Why digital biomarkers are the AI & ML strategy pharma should prioritise
Rather than chasing generative AI, pharma executives can focus their AI and machine learning (ML) strategies for drug development on investing in and deploying connected sensors to reduce costs and improve patient outcomes.
-
Outcome measures: Driving precision health strategies forward
ICON has been speaking, collaborating, and building with top pharma throughout the year to help them develop better drugs, faster, for patients. Here are a few observations from this year.
-
Digital endpoints widely adopted in pharmaceutical and biotech-sponsored clinical trials
Over 130 pharma and biotech organizations have relied on AI-powered digital biomarkers and sensor-derived clinical outcome assessments (COAs) to capture patient-centered endpoints.
-
Keeping up to date with the latest regulatory developments for decentralised clinical trials
This blog examines the crucial topic of regulating the use of DCTs, exploring what’s in place now and what sponsors need to consider as these methods continue to gain traction.
-
Best practices for KPI management in FSP partnerships
Learn more about the best practices for KPI creation and management in this blog.
-
A positive step for diversity and inclusion in clinical trials – reflections on FDORA
Read this blog for updated recommendations and additional guidance on DCTs to ensure equitable access to cutting-edge therapeutics and clinical trials.
-
Redefining sourcing model terminology
This blog explores the new framework for defining CRO sourcing models and explains its importance.
-
Challenges and key success factors for linguistic validation and COA translation within clinical trials
This blog outlines challenges and key success factors in the linguistic validation process.
-
Managed service providers
Managed Service Providers ensure our businesses have competitive advantage especially in the area of language and translation services.
-
Hassle-free medical and clinical trial translation services in the post-pandemic era
The Covid-19 pandemic has revealed the importance of medical translation as a mostly overlooked albeit essential service in the world of life sciences and healthcare.
-
How joint venture models can boost Japan’s pharmaceutical industry
Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.
-
Exploring the benefits of biotech partnerships
The biotechnology sector is leading the way in developing innovative therapies that will address the unmet needs of many challenging diseases.
-
Wearables across phases: How to best incorporate digital endpoints at every stage of clinical research
Once implemented properly, digital endpoints have the potential to enhance any trial, whether observational or interventional, or early or late phase.
-
Post pandemic clinical trial strategies: How COVID-19 altered clinical trials forever and what’s next
The COVID-19 pandemic forced the clinical trials industry to accept and accelerate the use of digital health technologies.
-
Wearables and digital endpoint generation
The key considerations that arise when using digital technology to support endpoint generation in clinical studies.
-
Top five digital technologies set to transform pharma R&D
The current wave of emerging digital technologies offers an opportunity to significantly disrupt pharma business operating models in a variety of ways.
